Search bioRxivSearch

bioRxiv · 10.1101/457416

Predicting response to motor therapy in chronic stroke patients using Machine Learning

Abstract

Accurate predictions of motor improvement resulting from intensive therapy in chronic stroke patients is a difficult task for clinicians, but is key in prescribing appropriate therapeutic strategies. Statistical methods, including machine learning, are a highly promising avenue with which to improve prediction accuracy in clinical practice. The first main objective of this study was to use machine learning methods to predict a chronic stroke individuals motor function improvement after 6 weeks of intervention using pre-intervention demographic, clinical, neurophysiological and imaging data. The second main objective was to identify which data elements were most important in predicting chronic stroke patients impairment after 6 weeks of intervention. Data from one hundred and two patients (Female: 31%, age 61{+/-}11 years) who suffered first ischemic stroke 3-12 months prior were included in this study. After enrollment, patients underwent 6 weeks of intensive motor and transcranial magnetic stimulation therapy. Age, gender, handedness, time since stroke, pre-intervention Fugl-Meyer Assessment, stroke lateralization, the difference in motor threshold between the unaffected and affected hemispheres, absence or presence of motor evoked potential in the affected hemisphere and various imaging metrics were used as predictors of post-intervention Fugl-Meyer Assessment. Five machine learning methods, including Elastic-Net, Support Vector Machines, Artificial Neural Networks, Classification and Regression Trees, and Random Forest, were used to predict post-intervention Fugl-Meyer Assessment based on either demographic, clinical and neurophysiological data alone or in combination with the imaging metrics. Cross-validated R-squared and root of mean squared error were used to assess the prediction accuracy and compare the performance of methods. Elastic-Net performed significantly better than the other methods for the model containing pre-intervention Fugl-Meyer Assessment, demographic, clinical and neurophysiological data as predictors of post-intervention Fugl-Meyer Assessment ([Formula]). Pre-intervention Fugl-Meyer Assessment and difference in motor threshold between affected and unaffected hemispheres were commonly found as the strongest two predictors in the clinical model. The difference in motor threshold had greater importance than the absence or presence of motor evoked potential in the affected hemisphere. The various imaging metrics, including lesion overlap with the spinal cord, largely did not improve the model performance. The approach implemented here may enable clinicians to more accurately predict a chronic stroke patients individual response to intervention. The predictive models used in this study could assist clinicians in making treatment decisions and improve the accuracy of prognosis in chronic stroke patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tozlu, C., Edwards, D., Boes, A., Labar, D., Tsagaris, K. Z., Silverstein, J., Lane, H., Sabuncu, M., Liu, C., Kuceyeski, A.. 2018-11-06. Predicting response to motor therapy in chronic stroke patients using Machine Learning. https://doi.org/10.1101/457416

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience